NorthCrest Asset Manangement’s Myriad Genetics MYGN Stock Holding History

NorthCrest Asset Manangement’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12,431	Closed	-$110K	–	651
2025 Q1	$110K	Buy	12,431 +316	+3%	+$3.79K	﹤0.01%	585
2024 Q4	$166K	Sell	12,115 -519	-4%	-$9.58K	0.01%	551
2024 Q3	$346K	Buy	12,634 +34	+0.3%	+$920	0.01%	457
2024 Q2	$308K	Hold	12,600	–	–	0.01%	450
2024 Q1	$269K	Sell	12,600 -400	-3%	-$8.6K	0.01%	463
2023 Q4	$249K	Hold	13,000	–	–	0.01%	472
2023 Q3	$209K	Sell	13,000 -250	-2%	-$4.76K	0.01%	481
2023 Q2	$307K	Hold	13,250	–	–	0.01%	439
2023 Q1	$308K	Buy	13,250 +1,300	+11%	+$26.4K	0.01%	441
2022 Q4	$173K	Buy	11,950 +1,550	+15%	+$28.9K	0.01%	381
2022 Q3	$198K	Hold	10,400	–	–	0.01%	422
2022 Q2	$189K	Hold	10,400	–	–	0.01%	421
2022 Q1	$262K	Buy	+10,400	New	+$266K	0.01%	372

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

NorthCrest Asset Manangement's MYGN Position: Q2 2025 in Review

NorthCrest Asset Manangement sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 12,431 shares — an estimated $110K sold.

NorthCrest Asset Manangement first reported a position in MYGN in Q1 2022 and held it in 13 quarters. The position peaked at $346K in Q3 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

NorthCrest Asset Manangement reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
NorthCrest Asset Manangement sold 12,431 Myriad Genetics shares in Q2 2025, an estimated $110K.
NorthCrest Asset Manangement first reported a position in Myriad Genetics in Q1 2022 and held it in 13 quarters.
NorthCrest Asset Manangement's Myriad Genetics position peaked at $346K in Q3 2024.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on NorthCrest Asset Manangement's 13F filing for Q2 2025, filed 10 Jul 2025.